Atlas Trials

The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus

Clinical trial NCT06851611 · COMPLETED

Trial details

NCT number
NCT06851611
Sponsor
Rokote Laboratories Finland Oy
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
COVID19, Sars-Cov-2
Start date
2025-01-21
Primary completion
2025-06-25
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.